H.C. Wainwright raised the firm’s price target on Catalyst Pharmaceuticals to $30 from $26 and keeps a Buy rating on the shares. Given Agamree’s current momentum, the firm expects the strong launch to continue throughout 2024 and beyond.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals price target raised to $30 from $25 at Truist
- Catalyst Pharmaceuticals price target raised to $31 from $27 at Citi
- Catalyst Pharmaceuticals backs FY24 revenue view $455M-$475M,
- Catalyst Pharmaceuticals reports Q2 EPS 33c, consensus 26c
- Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update